1 / 3

Transcatheter Cardiovascular Therapeutics – TCT 2008 October 12-17, 2008 Washington, DC, USA

SOS – A Prospective Randomized Trial of Paclitaxel-Eluting Stent vs. Bare-Metal Stent in Saphenous Vein Grafts Lesions. PI: Emmanouil S. Brilakis, MD, PhD. Design: Prospective, randomized, multicenter trial (4US / 1EU centers).

ulysses-miller
Download Presentation

Transcatheter Cardiovascular Therapeutics – TCT 2008 October 12-17, 2008 Washington, DC, USA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SOS – A Prospective Randomized Trial of Paclitaxel-Eluting Stent vs. Bare-Metal Stent in Saphenous Vein Grafts Lesions PI:Emmanouil S. Brilakis, MD, PhD Design:Prospective, randomized, multicenter trial (4US / 1EU centers) Objective: To compare the 12month angiographic and 24month clinical outcomes between PES and BMS in SVG lesions Mod-high Risk Population 44% Diabetes* > 50% ACS* SVG age > 10y* Embolic protection devices > 50%* *both groups/ p ns Transcatheter Cardiovascular Therapeutics – TCT 2008 October 12-17, 2008 Washington, DC, USA

  2. SOS – A Prospective Randomized Trial of Paclitaxel-Eluting Stent vs. Bare-Metal Stent in Saphenous Vein Grafts Lesions Primary Endpoint : Binary Angiographic Restenosis % relative risk: 0.18 95% CI: 0.07, 0.48 p < 0.0001 Transcatheter Cardiovascular Therapeutics – TCT 2008 October 12-17, 2008 Washington, DC, USA

  3. SOS – A Prospective Randomized Trial of Paclitaxel-Eluting Stent vs. Bare-Metal Stent in Saphenous Vein Grafts Lesions Primary Endpoint: Clinical Outcomes (median follow-up 1.5 years) Conclusion: In SVG lesions, compared to BMS, the Taxus PES resulted in significant reduction in 12-month angiographic restenosis and TLR. Transcatheter Cardiovascular Therapeutics – TCT 2008 October 12-17, 2008 Washington, DC, USA

More Related